BBNXBeta Bionics, Inc.
Price
-21%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
A flag to check, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
Beta Bionics, Inc. (BBNX) reported revenue of $32M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 59% and net loss of $23M. For the full year FY2025, revenue was $100M (+54% year on year) and net income −$73M. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 17, 2026On September 15, 2026, Beta Bionics, Inc. (the “Company,” “we,” “our” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co., Wells Fargo Securities, LLC and Leerink Partners LLC, as representatives of the several underwriters named therein …Other event · Form 8-K
- Sep 15, 2026Mint Approval and Commercial Launch On September 14, 2026, we announced FDA clearance of Mint, our patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and …Regulation FD disclosure · Form 8-K
- Jul 29, 2026Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Devices
The closest names by size in the same industry